Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP)

Disc Medicine announced it will host a webcast on October 19, 2026 at 8:00 a.m. ET to discuss topline results from the APOLLO Phase 3 trial of bitopertin in erythropoietic protoporphyria (EPP). Bitopertin is an oral GlyT1 inhibitor in-licensed from Roche in 2021, and if successful could be the first disease-modifying therapy for EPP.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.